Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | VNN1 | O95497 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206266 | 0.83 | KCNQ3 (0.54) | CNR2VNN1SRD5A2CES2MEN1 | |
| SCHEMBL5206965 | 0.77 | CNR2 (0.47) | CNR2VNN1SRD5A2CES2MEN1 | |
| SCHEMBL5207410 | 0.76 | CNR2 (0.46) | CNR2VNN1SRD5A2CES2MEN1 | |
| SCHEMBL27443558 | 0.74 | MEN1 (0.52) | CNR2VNN1SRD5A2CES2MEN1 | |
| SCHEMBL6182752 | 0.72 | NPSR1 (0.55) | MEN1ALDH1A1CYP1A2MAPTKMT2A | |
| SCHEMBL5203839 | 0.72 | CYP1A2 (0.46) | CYP1A2CYP3A4 | |
| SCHEMBL5249070 | 0.72 | TRPV3 (0.43) | TRPV1MEN1MAPTKMT2APTGS1 | |
| SCHEMBL5204620 | 0.72 | LMNA (0.45) | — | |
| SCHEMBL2941622 | 0.71 | SRD5A2 (0.81) | CNR2VNN1SRD5A2CES2MEN1 | |
| SCHEMBL1237189 | 0.71 | SRD5A2 (0.79) | CNR2VNN1SRD5A2CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | claimed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | claimed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | claimed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | claimed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | claimed |
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | disclosed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | PYM1, Q6ZSR9, MRM1 | CNR2 1353/4885VNN1 4066/4885TRPV1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.